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Abstract
Background: Abdominoperineal resection (APR) for rectal cancer is associated with high morbidity of the perineal
wound, and controversy exists about the optimal closure technique. Primary perineal wound closure is still the
standard of care in the Netherlands. Biological mesh closure did not improve wound healing in our previous
randomised controlled trial (BIOPEX-study). It is suggested, based on meta-analysis of cohort studies, that filling of
the perineal defect with well-vascularised tissue improves perineal wound healing. A gluteal turnover flap seems to
be a promising method for this purpose, and with the advantage of not having a donor site scar. The aim of this
study is to investigate whether a gluteal turnover flap improves the uncomplicated perineal wound healing after
APR for rectal cancer.
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Methods: Patients with primary or recurrent rectal cancer who are planned for APR will be considered eligible in
this multicentre randomised controlled trial. Exclusion criteria are total exenteration, sacral resection above S4/S5,
intersphincteric APR, biological mesh closure of the pelvic floor, collagen disorders, and severe systemic diseases. A
total of 160 patients will be randomised between gluteal turnover flap (experimental arm) and primary closure
(control arm). The total follow-up duration is 12 months, and outcome assessors and patients will be blinded for
type of perineal wound closure. The primary outcome is the percentage of uncomplicated perineal wound healing
on day 30, defined as a Southampton wound score of less than two. Secondary outcomes include time to perineal
wound closure, incidence of perineal hernia, the number, duration and nature of the complications, re-
interventions, quality of life and urogenital function.
Discussion: The uncomplicated perineal wound healing rate is expected to increase from 65 to 85% by using the
gluteal turnover flap. With proven effectiveness, a quick implementation of this relatively simple surgical technique
is expected to take place.
Trial registration: The trial was retrospectively registered at Clinicaltrials.gov NCT04004650 on July 2, 2019.
Keywords: Abdominoperineal resection, Rectal cancer, Primary perineal wound closure, Gluteal turnover flap,
Perineal wound infection and perineal wound healing
Background
Historically, abdominoperineal resection (APR) has been
the standard treatment for (low) rectal cancer. Although
most rectal cancer patients nowadays undergo a restora-
tive total mesorectal excision (TME), an APR is still
performed in selected patients with very low tumours
and/or poor sphincter function. A drawback of APR is
the resulting perineal defect that still poses a high risk of
morbidity, especially in patients who have undergone
pre-operative (chemo)radiotherapy [1]. Early perineal
wound complications occur in up to 35% of patients,
and 10% of patients still have a wound complication
even 1 year after the operation [2, 3].
The high rate of perineal morbidity after primary
wound closure has resulted in a continuous discussion
on alternative closure methods for the perineal wound
after APR. Options include biological mesh closure and
(muscle) flap assisted closure. Biological mesh closure
has been investigated in our previous randomised
controlled trial (BIOPEX-study), and showed no super-
iority in perineal wound healing compared to primary
closure. Biological mesh closure did result in a lower
perineal hernia rate 1 year after APR (13% versus 27%;
P = 0.0316) [2]. The absence of improvement in perineal
wound healing after biological mesh closure is probably
related to the formation of a dead space between the
mesh and the perineal skin after APR. This dead space is
prone to fluid accumulation, which can subsequently get
infected with abscess formation.
The hypothesis is that filing of the dead space by well-
vascularised soft tissue can prevent fluid accumulation,
and thereby reduce infectious complications and abscess
formation. Several myocutaneous and fasciocutaneous
flaps have been used for this purpose. In a systematic
review of cohort studies, muscle flap closure of the
perineal wound showed an improvement of 20%
compared to primary closure of perineal defects after
oncological resection [4]. However, downsides of these
flaps are the donor-site and recipient-site morbidity that
are both often neglected, besides the complexity of the
reconstructive procedures with the need for the presence
of a plastic surgeon, and substantially increased opera-
tive time. Especially in the case of a rectus abdominis
muscle flap, the flap interferes with the benefits of a
laparoscopic approach of the APR and gives a high risk
of donor site morbidity. Furthermore, there might be an
impact on cosmesis due to an additional scar.
A gluteal turnover flap is a small transposition flap
consisting of the adjacent skin and subcutaneous tissue
of one of the buttocks. This flap is deepithelialised and
dissected down to the gluteal muscle, it is perfused
through perforating blood vessels from the underlying
muscle. The flap is hinged into the resected space of the
anal sphincter complex, and the dermis is stitched to the
contralateral levator remnant as a pelvic floor closure.
The skin is closed in layers over the flap in the midline,
thereby not creating an additional scar, and minimizing
donor-site morbidity. Moreover, it is a relatively simple
procedure, which is easy to learn, and can be performed
without the need of a plastic surgeon.
Potentially, the gluteal turnover flap both improves
wound healing by filling the dead space, as well as pre-
venting hernia formation by stitching deepithelialised
dermis to the levator remnant. A pilot study of this
gluteal turnover flap showed no flap necrosis, and no
major morbidity requiring radiological or surgical re-
intervention within 30 days [5].
The aim of this randomised controlled multicentre
trial is to compare the effect of gluteal turnover flap
closure of the perineal wound with primary perineal
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The objective of this study is to investigate the effect of
gluteal turnover flap closure of the perineal wound with
primary closure of the perineal wound after APR for
rectal cancer. The hypothesis is that gluteal turnover flap
reconstruction increases the uncomplicated perineal
wound healing rate, and decreases the occurrence of
perineal hernia.
Design
In this multicentre, single-blind, randomised controlled
trial, patients will be randomised between gluteal turn-
over flap closure (experimental arm) and primary wound
closure (control arm) (Fig. 1). A block randomisation of
1:1 will be used, stratified for primary or recurrent rectal
cancer and neo-adjuvant (chemo)radiotherapy. The pa-
tient is blinded to the allocation of treatment. The study
will be carried out in five academic centres, 11 teaching
hospitals and two non-teaching hospitals. In centres
without experience in gluteal turnover flap reconstruc-
tion, the procedure will be supervised by one of the prin-
cipal investigators (PJT or RH) or the plastic surgeon
(OL) until a standardised and quality controlled gluteal
turnover flap procedure is assured.
Perineal wound healing will be assessed at 14 days, and
1, 3, 6 and 12 months postoperatively using the South-
ampton wound score (Table 1). Evaluation will be
performed by an independent observer not aware of
treatment allocation. The perineal wound will be scored
with regard to complications and hernia. In addition, a
photograph of the perineal wound will be made. A CT-
scan will be performed according to the follow-up, and
will be assessed for the occurrence of presacral or peri-
neal abscesses and perineal herniation. Quality of Life
and urogenital questionnaires will be collected at each
follow-up moment (EQ-5D, EORTC-30, EORTC-29,
SF36, UDI-6, IIQ-7, IIEF, FSFI, FSDS-R). Additionally,
all perineal wound events, re-admissions and re-
interventions will be scored.
Study population
Patients with the following criteria are eligible for inclu-
sion: resection of primary or recurrent rectal cancer by
APR, age of 18 years or older, ability to complete follow-
up, and written informed consent. Exclusion criteria are
total pelvic exenteration or sacral resection above level
S4/S5, resection by an intersphincteric APR, biological
mesh closure of the pelvic floor, severe systemic diseases
affecting wound healing except for diabetes (i.e. renal
failure requiring dialysis, liver cirrhosis, and immune
compromised status like HIV), collagen disorders (i.e.
Marfan syndrome, Ehler-Danlos syndrome) and enrol-
ment in other trials with the same primary endpoint.
Treatment strategies
In both study arms, APR can start with either the
abdominal or the perineal phase. The abdominal phase
of the APR can be performed via either laparoscopic or
open surgery. The extent of perineal skin excision will
be as limited as oncologically justified. The perineal
phase of the APR will be performed according to the
principles of a complete or limited extralevator APR.
This means that the levator muscles will be transected
laterally on both sides in order to leave a muscular cuff
all around the resection specimen, or that part of the le-
vator muscles will be resected only at the side of the
tumour. Routine removal of the coccyx will not take
place, unless based on oncological principles or needed
to improve surgical visibility. An omentoplasty will not
routinely be performed. A transabdominal drain will be
placed and removed after 4 days or when the drain
production is beneath 100 cc/24 h. The APR specimens
will be classified according to Phil Quirke’s classification
[6]. Postoperatively, the Enhanced Recovery After
Surgery (ERAS) protocol will be followed and the
sutures will be removed after 14 days at the outpatient
clinic.
Perineal closure control arm
Standard practice in the Netherlands and the participat-
ing centre in the UK is primary closure of the perineum.
This consists of stitching the perineal ischioanal fat
together using interrupted 2.0 Vicryl sutures. After-
wards, the subcutaneous fat will be closed using inter-
rupted 2.0 Vicryl sutures. A Redon drain (CH10) will
standardly be placed between these layers. Subsequently,
the skin will be closed using interrupted Vicryl 3.0
sutures. The perineal redon suction drain will be
removed after 14 days or when the production is less
than 30 cc/24 h.
Perineal closure experimental arm
Perineal closure will be performed or supervised by a
surgeon experienced with the gluteal turnover flap. The
first gluteal turnover flap procedure at a local participat-
ing hospital will always be supervised by an experienced
(plastic) surgeon from the study group. When experi-
ence with the flap is not sufficiently present after the
first time, supervision will be continued as long as re-
quired. The patient will be positioned either in prone or
lithotomy position as preferred by the operating surgeon.
The flap is marked on the gluteal skin on either the right
or the left side of the surgical defect with a maximum
width of about 2.5 cm. The half-moon shaped skin island
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is deepithelialised. Subsequently, the flap is developed by
incising the dermis and subcutaneous fat with approxi-
mately a 45 degree level towards lateral. Gluteal perfora-
tors are not selectively dissected, and for this reason
there is no need for pre-operative Doppler identification
of perforators, which simplifies the procedure. Once
developed, the subcutaneous flap is placed into the peri-
neal defect and the deepithelialised dermis is fixed to the
contralateral pelvic floor remnant with Vicryl 2.0
sutures. Afterwards, the perineum is closed in layers
over the gluteal flap using interrupted 2.0 Vicryl sutures
for the subcutaneous fat and Vicryl 3.0 interrupted
sutures for the skin. A Redon drain (CH10) will stand-
ardly be placed between the flap and the subcutaneous
fat and removed after 14 days or when the production is
less than 30 cc/24 h. The procedure with accompanying
video has been published previously [7].
Outcome parameters
Primary endpoint
The primary endpoint of the study is the percentage of
uncomplicated perineal wound healing at 30 days post-
operatively. Uncomplicated perineal wound healing is
defined as a Southampton wound score of less than two.
Secondary endpoints
Secondary endpoints are perineal wound healing accord-
ing to the Southampton wound grading at 14 days, 3, 6
Fig. 1 Flow-diagram: study design
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and 12 months postoperatively; postoperative pain score,
the effect of neo-adjuvant treatment on perineal wound
healing, incidence of persistent perineal or presacral si-
nuses both clinically and by imaging (routine follow-up
CT), need for re-intervention or re-admission related to
perineal wound problems, incidence of symptomatic and
asymptomatic perineal hernia during follow-up, length
of hospital stay, and quality of life and urogenital func-
tion (EQ-5D, EORTC-30, EORTC-29, SF36, UDI-6, IIQ-
7, IIEF, FSFI, FSDS-R).
Sample size calculation
The proportions of patients with uncomplicated perineal
wound healing between both study arms will be
compared and analysed by the intention-to-treat
approach. The hypothesis is that gluteal turnover flap
closure increases the uncomplicated perineal wound
healing rate compared to primary closure of the
perineum.
Our recently conducted pilot study showed promising
results of the gluteal turnover flap with a flap failure in
zero of ten patients included, and no Clavien-Dindo
complications of three or higher within 30 days of
surgery. Among the ten patients, there were four minor
complications and no major wound complications re-
quiring re-intervention at 30 days postoperatively. The
minor complications consisted of two perineal wound
dehiscences, one perineal infection necessitating manual
drainage and antibiotic therapy, and one non-infected
perineal seroma that also required manual drainage. A
recent published case series of 13 patients undergoing
an APR for rectal cancer with a similar flap procedure
showed no cases of flap loss and no donor site or major
perineal morbidity [8]. Combining the outcome of our
pilot study with the recently published case series results
in an uncomplicated wound healing rate of 83% (19/23).
In current literature an increase of uncomplicated
perineal wound healing of approximately 20% is to be
expected when a muscle flap is being used. However,
these data are mostly derived from cohort series in
which different kinds of flaps were being used, with
different definitions of complicated perineal wound
healing. Therefore the currently available literature is
difficult to interpret with regard to perineal wound heal-
ing. In our previously conducted randomised controlled
trial (the BIOPEX-study), there was an uncomplicated
perineal wound healing percentage of 66% after primary
perineal wound closure. Extrapolating the reported im-
provement in perineal wound healing, a total number of
146 patients (73 per group) are needed to be able to de-
tect a 20% increase in primary perineal wound healing
by use of a gluteal turnover flap (from 65 to 85%), apply-
ing a Chi-Square test with a two-sided 0.05 significance
level and with 80% power. With an estimated drop-out




An intention-to-treat analysis will be performed on the
primary outcome using a two-sided Chi-square test to
compare the two study groups. A p-value of < 0.05 is
considered statistically significant. Specific wound
complications will be compared between the groups as
categorical variables using the Mann-Whitney U test. A
Kaplan-Meier survival analysis will be used to analyse
Table 1 Southampton wound scoring system
Grade Appearance
0 – Normal healing
1 – Normal healing with mild bruising or erythema A – some bruising
B – considerable bruising
C – mild erythema
2 – Erythema plus other signs of inflammation A – at one point
B – around sutures
C – along wound
D – around wound
3 – Clear or haemoserous discharge A – at one point only (< 2 cm)
B – along wound (> 2 cm)
C – large volume
D – prolonged (> 3 days)
4 – Pus/purulent discharge A – at one point only (< 2 cm)
B – along wound (> 2 cm)
5 – Deep or severe wound infection with or without tissue breakdown
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the differences in time to perineal wound healing be-
tween the two study groups. Statistical analyses will be
performed using SPSS software for Windows version 26.
Secondary endpoints
Relative risk with 95% confidence interval will be used to
analyse treatment effect according to intention-to-treat.
Analysis of binary secondary outcome measures will be
performed similar to the primary outcome (such as peri-
neal hernia rate, re-intervention rate, wound complica-
tion etc.). All p-values will be two-tailed and a p-value of
< 0.05 will be considered statistically significant.
Subgroup analyses will employ a test of interaction to
explore whether there is evidence that the treatment
effects differ across subgroups. As with all subgroup ana-
lyses these will be interpreted with caution, and will be
considered hypothesis generating.
Quality of life and urogenital function
Graphic representation will be used to portray quality of
life and urogenital function data (EQ-5D, EORTC-30,
EORTC-29, SF36, UDI-6, IIQ-7, IIEF, FSFI, FSDS-R)
across all follow-up moments, analysed according to the
manuals, and will presented as domain and summarised
scores. Questionnaire outcome comparisons will be ana-
lysed using linear mixed models. All analyses will be ac-
cording to the intention-to-treat principle.
Data monitoring
An independent Data Safety Monitoring Board (DSMB)
committee has been established to perform ongoing
safety surveillance and interim analyses on the safety
data. The DSMB is composed of two independent clini-
cians and one independent epidemiologist. None of the
members has conflict of interest with the sponsor of the
study. An interim analysis will be performed at 80 in-
cluded patients (of the total of 160 patients). The steer-
ing committee will be supplied with the number of
(serious) adverse events in both groups. If there is a
skewed distribution of the number of (serious) adverse
events between the two groups, an efficacy analysis can
be performed at the discretion of the steering commit-
tee. Following these interim analyses, the steering com-
mittee will advise upon continuation of the trial.
Ethics and safety
The study protocol (NL65461.018.18) has been ap-
proved by the medical ethical committee of the Aca-
demic Medical Centre, Amsterdam, the Netherlands.
This study will be performed according to the princi-
ples of Good Clinical Practice.
Discussion
A variety of techniques have been described for closure
of the perineal defect following APR for rectal cancer.
To date there is only one published randomised con-
trolled trial on perineal wound closure after APR [2].
This study compared biological mesh closure with pri-
mary wound closure, and showed no improvement in
primary wound healing after biological mesh closure.
The absence of an effect is probably related to the prop-
erties of the mesh: a mesh adds strength to the pelvic
floor, but does not fill the perineal defect. There is still a
possibility of fluid accumulation in the perineal defect
with the risk of secondary contamination.
Since it is thought that filling of the perineal defect is
needed to prevent fluid formation, other perineal closure
methods, such as autologous tissue flap closures are be-
ing increasingly used. A number of musculocutaneous
transposition flaps and fasciocutaneous perforator flaps
can be used for perineal closure after APR. The rectus
abdominis muscle flap, gracilis flap, lateral thigh flap and
the gluteal flap have all been described for this purpose
[9–15]. The vertical rectus abdominis muscle (VRAM)
flap is one of the flaps most often used for closure of
relatively large perineal defects. It is well-vascularised,
with sufficient vascular pedicle length and bulk, however
it disturbs the abdominal wall integrity. In the era of lap-
aroscopic rectal cancer surgery, a VRAM flap for routine
perineal closure seems to be too invasive with relatively
high donor site morbidity. Furthermore, failure rates as
high as 15% have been reported [9, 13, 16].
The gracilis flap can provide good coverage for the an-
terior perineal wound. However, due to the distal posi-
tioning of the vascular pedicle the mobility is restricted,
limiting its use for filling the perineal defect. According
to the current literature, the lateral thigh flap is also a
good alternative for the reconstruction of the perineum.
It may prevent perineal herniation due to the strong ten-
sor fasciae latae [9]. Although promising, the literature
on this topic is scarce, especially in oncological patients.
Besides that, the lateral thigh flap is most often
performed by a plastic surgeon, has a difficult closure of
the donor site, may require an additional skin graft and
substantially increases surgery duration and patient
morbidity.
Finally, a gluteal flap can be used for perineal closure
after APR and can be performed as a perforator flap
(IGAP/SGAP) or a myocutaneous flap [17]. The gluteal
perforator flap lies outside the radiated field and trans-
fers solely well-vascularised skin and subcutaneous tissue
into the perineal wound. Due to the transfer of only skin
and subcutaneous tissue, patients experience less pain
and morbidity at the donor site compared to the gluteal
myocutaneous flap [8, 18]. The gluteal myocutaneous
flap has more bulk upon positioning in the pelvic
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wound, but due to the atrophy of the muscle the myocu-
taneous flap loses its size over time. Furthermore, the
gluteal myocutaneous flap results in a big scar on the
buttock with implications for daily life activities.
A recent meta-analysis of ten studies, including 8 stud-
ies using VRAM flap and 2 studies using gracilis flaps,
found a significant reduction in perineal complications
by flap reconstruction after APR compared to primary
perineal wound closure (pooled perineal wound compli-
cation rate of 35% versus 52%, OR 2.17 (95% CI 1.49–
3.15), heterogeneity I2 = 0%) [11]. Especially the major
perineal wound complications were reduced (pooled
proportions of 8% vs 25%, OR 3.64 (95% CI 1.70–7.79),
I2 = 0%). The drawback of the current flap series is that
they often lack control, and often describe selective pop-
ulations with larger defects which makes comparison
difficult. Moreover, no randomised controlled trials
comparing muscle flaps to other techniques have been
published until now. Currently, there is one other open
trial (trial registration number: NCT01347697), which
started approximately 5 years ago, and randomises be-
tween gluteus maximus myocutaneous flap and acellular
porcine collagen implant [19].
The perineal dead space after APR is often relatively
limited and does not routinely require a large bulky tis-
sue flap. A flap should therefore be relatively simple to
perform, requiring only limited additional operative
time, should be able to be combined with laparoscopic
surgery and performed in both prone and supine posi-
tions, and should not add additional scars. The gluteal
turnover flap, which constitutes the experimental inter-
vention in the present trial, is a modified perforator flap
which fulfils these criteria [8]. The gluteal turnover flap
seems to be a promising method for the purpose of
routine perineal closure after APR for primary and re-
current rectal cancer that does not require exenterative
procedures. In addition to its positive effect on the peri-
neal wound healing, it is expected that perineal hernia
incidence will be reduced, by anchoring the strong der-
mis onto the contralateral remnant of the levator ani.
The use of neo-adjuvant therapy in the Netherlands
has been reduced in the last couple of years. Therefore,
non-radiated patient are also considered eligible in the
BIOPEX-2, while only radiated patients were included in
the BIOPEX trial. Neo-adjuvant therapy is one of the
most import risk factors for perineal wound complica-
tions, and stratification will be used to balance the study
arms for this factor.
It was decided to use the same control intervention in
the BIOPEX-2 trial as used in the BIOPEX trial, namely
primary perineal closure. The main reason was because
no superiority of biomesh closure on the primary
endpoint could be demonstrated. Although a significant
difference in perineal hernia rate was found for the
experimental arm in the BIOPEX study as a secondary
finding, biological mesh closure did not become the
standard of care in the Netherlands. The relatively high
costs and relatively small absolute difference in perineal
hernia rate were the main reasons for continuing
primary closure as routine daily care in most Dutch in-
stitutions. Furthermore, the reduced perineal hernia rate
needs further confirmation by long-term follow-up.
In conclusion, tissue flaps used to fill perineal dead
space have been suggested to improve perineal wound
healing, but currently used flaps are relatively invasive
and have several drawbacks. The gluteal turnover flap
seems to be a promising method, which is less invasive,
does not add donor site scarring, and is relatively easy to
perform. High quality evidence on its efficacy is needed,
for which reason the BIOPEX-2 has been designed.
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